Research
Cytokinetics Presents Data from the Phase 2 Clinical Trial of Reldesemtiv (CK-2127107) in Patients with SMA at the 2018 Annual SMA Conference
Today, Cytokinetics announced data from the Phase 2 clinical study of reldesemtiv in patients with SMA, presented in an oral presentation by John W. Day, […]
Read More ›Biogen to Present New Data at the 2018 Annual SMA Conference
Yesterday, Biogen announced it will present data from its SPINRAZA clinical development program –the largest of its kind, with more than six years of data–for […]
Read More ›Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
Scholar Rock, a biotechnology company based in Boston, recently announced that it has completed dosing of the first cohort and is continuing enrollment of healthy […]
Read More ›Roche Releases Community Statement on Olesoxime Program
Roche today provided the following community statement on olesoxime. Dear members of the SMA Community, We would like to provide you with an update about […]
Read More ›Cure SMA Awards $150,000 Grant to Kathryn Swoboda, MD, Massachusetts General Hospital
Cure SMA has awarded a $150,000 research grant to Kathryn Swoboda, MD, at the Massachusetts General Hospital, for her project, “Clinical and pathologic correlations in […]
Read More ›Biogen Releases Community Statement on Spinraza Access and New Data
Biogen has released the following community statement on Spinraza access and new research data. Dear Members of the SMA community, Thank you for your continued […]
Read More ›Cure SMA Awards $150,000 Grant to Chad Heatwole, MD, University of Rochester
Cure SMA has awarded a $150,000 research grant to Chad Heatwole, MD, at the University of Rochester, for his project, ” Development of a Clinically […]
Read More ›Invitae Partners with Biogen to Offer Free Genetic Testing for SMA
Invitae Corporation recently announced that it will partner with Biogen to offer genetic testing at no charge to patients who may have spinal muscular atrophy […]
Read More ›Dr. Richard Finkel, M.D., Honored with the American Academy of Neurology’s 2018 Sidney Carter Award in Child Neurology
Richard Finkel, M.D., the chief of neurology at Nemours Children’s Hospital in Orlando, Fla., was honored with the American Academy of Neurology’s 2018 Sidney Carter […]
Read More ›The Discovery of Spinraza
SMA is caused by a mutation in the survival motor neuron gene 1 (SMN1). In a healthy person, this gene produces a protein—called survival motor […]
Read More ›